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Biotechnological  tools  such  as
biocompatible nanoparticles  have
promising potential  for  theranostic
strategies.
Our study  demonstrates  the  appli-
cation of  speciﬁcally  constructed
nanoparticles in  the  form  of tunable
plasma lipoproteins.
Tuning  of  phosphatidylcholines  and
apolipoprotein B100  on nanoparti-
cle surfaces  is  especially  helpful  for
delivery route  of  glial  precursor  cells.
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a  b  s  t  r  a  c  t
Brain  development  and  maintenance  requires  transportation  of cerebral  sustenance  across  the
blood–brain  barrier.  Disorders  of this  process  can  induce  neurodegenerative  diseases,  which  can  affect
numerous  patients  and  incur  signiﬁcant  treatment  expenses.  Recent  scientiﬁc  advances  suggest  that
knowledge  of this  transportation  will lead  to  the development  of  tailor-made  theranostic  strategies.
Biotechnological  tools  such  as biocompatible  nanoparticles  have promising  potential  in  this  context,
however,  information  about  their  consequences  in  the  brain  is  largely  unknown.  The  present  study
demonstrates  the  application  of  speciﬁcally  constructed  cerebral  sustenance  nanoparticles  in the formanoparticle
lia
lood–brain  barrier
urfactant
ipoprotein
of  tunable  plasma  lipoproteins  to provide  information  about  their  pathways  to the  brain  and  delivery
to  glia  cells.  Individual  cell  analysis  in  brain  sections  enabled  us to understand  the  accumulation  of tun-
able  plasma  lipoproteins  in  the  cerebral  cortex,  striatum,  and  cerebellum,  which  have  been previously
identiﬁed  as  the  incident  regions  of  Alzheimer’s  disease,  Parkinson’s  disease,  and  spinocerebellar  ataxia.
The  adjustability  of  the  tunable  plasma  lipoproteins  enables  their  use  in theranostic  applications  against
neurodegenerative  diseases.© 2013
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. Introduction
The brain regulates mental and motor functions, which are
ased on neural networks. Neural network changes such as synap-
ogenesis, myelination, and neuro- and glio-genesis are associated
ith environmental factors and individual life events [1]. These
hanges are produced and preserved by cerebral sustenance trans-
ortation across the blood-brain barrier (BBB) [2]. It is generally
nown that glial cells such as astrocytes and oligodendrocytes
lay  roles in brain development and maintenance [3]. They are
ot only relevant to the functions of synaptogenesis, myelination,
nd BBB, but are also involved in the pathogenesis of Alzheimer’s
isease (AD), Parkinson’s disease (PD), and progressive spinocere-
ellar ataxia (SCA) [2,3]. In addition, it suggests that AD, PD,
nd SCA generation are induced by the loss of synapses and
yelin or the malfunction of BBB in the brain [2,3]. Glial cells
re responsible for the preservation of synapses, myelin, and
BB [2,3]. Therefore, innovation to achieve the aim of deliver-
ng drugs to glial cells will lead to key advancements in the
evelopment of effective theranostic methods [3,4]. However, the
athway from the plasma to glial cells for delivering drugs is as yet
nknown.
Neurodegenerative diseases (NDs) such as AD, PD, and SCA are
trongly associated with brain aging. These pathological pheno-
ypes have been found in speciﬁc brain regions such as the cerebral
ortex (AD), striatum (PD), and cerebellum (SCA) [5,6]. Clinical
tudies suggest that low vitamin A, D, and E levels in plasma con-
ribute to AD, PD and SCA pathogenesis [5,6]. Since mammals are
ot able to synthesize essential substances such as fat-soluble vita-
in  A, D, and E, they must be extracted from their diet in the form
f plant carotenes or animal retinyl esters, which are stored as
etinoids in the liver following ingestion. These vitamins are sub-
equently transported by plasma lipoproteins (PLs) from the liver
nto the cardiovascular system [7,8]. But, incorporation of vitamin
, D, and E into PLs through retinol-binding proteins, vitamin D-
inding proteins, and -tocopherol transfer proteins are impaired
n AD, PD, and SCA [5,6]. Moreover, it is widely accepted that vita-
in A, D, and E are required for synaptogenesis, myelination, and
lio-differentiation [9]. Consequently PLs that carry vitamins across
he BBB could be vital for glial cells such as astrocytes and oligo-
endrocytes.
PL core consists mainly of triglycerides, (esteriﬁed) cholesterols,
at-soluble vitamins, fatty acids, and hormones, while the shell is
omposed of phospholipids, primarily phosphatidylcholines (PCs)
nd sphingomyelins, and apolipoproteins (Apos), such as Apo-
1-4, Apo-B48, Apo-B100, Apo-C1-3, ApoD, Apo-E2-4, and Apo-J
7,8]. PLs in plasma are found in high-density lipoproteins (HDLs),
ow-density lipoproteins (LDLs), intermediate-density lipoproteins
IDLs), very low-density lipoproteins (VLDLs), and chylomicrons.
DLs, IDLs, and VLDLs, which carry fat-soluble vitamins, mainly
ontain Apo-B100 [7,8]. Here, we hypothesize that PCs and Apo-
100 in LDLs would be targetor for glial cells. There is now evidence
hat glial cells highly express heparan sulfate proteoglycans and
hondroitin sulfate proteoglycans, which can bind to LDLs [10,11].
nfortunately, LDL pathway to glial cells has yet been uncharacter-
zed.
In previous studies of brain delivery system, it has been
hown that the modiﬁcations of nanoparticle surfaces are common
pproach to achieve novel drug therapies for delivering nanopar-
icles to the brain [12–15]. Actually, polysorbate 80 with Apo-B or
po-E-mediated transport at the BBB has been demonstrated as
argets for nanoparticle delivery to the brain [12]. However, it has
een suggested that the polysorbate 80 induce toxic affects on the
BB permeability [12]. Therefore, future study for novel modiﬁca-
ion of nanoparticle surfaces should be focus on. Moreover, gold
anoparticles (AuNPs) are useful for the development of clinicalochem. Eng. Aspects 442 (2014) 157– 163
applications  and treatment strategies, since AuNPs are intended for
practical use as contrast agents for an X-ray computed tomography
(CT) [16–18].
Here our study demonstrates the application of specif-
ically constructed cerebral sustenance nanoparticles in the
form of tunable plasma lipoproteins (TPLs) in order to brain
delivery system speciﬁcally targeting a subpopulation of glial
cells.
2. Materials and methods
2.1.  Preparation and characterization of tunable plasma
lipoproteins
AuNPs of 20 nm diameter were produced by the Turkevich
method [19] and were diluted to a ﬁnal concentration of 500 g/ml.
PCs (850325P, Avanti Polar Lipids, USA) were dissolved by vortex-
ing in distilled water (ppb level) to a concentration of 1 mg/ml at
37 ◦C. Aggregates were removed by ﬁltration through a 100 nm
cutoff ﬁlter (SLVV033RS, Millipore, USA). A 400 l aliquot of the
resulting solution was  added to 100 l of the AuNPs. The AuNPs
were coated with the PCs by stirring overnight at 37 ◦C. The sizes
and shapes of the resulting TPLs were determined via transmis-
sion electron microscopy (TEM) (JEM-1200 EXII, JEOL, Japan) with
negative staining with uranyl acetates. The cell tracker, CM-DiI
(DiI) (C7000, Molecular ProbesTM, USA), was added at a rate of
0.5 l per 500 l of distilled water from a 1 mg/ml stock solu-
tion in DMSO. Next, 500 l of the diluted DiI-solution was mixed
with 500 l of the PC-coated AuNPs by gentle stirring, followed by
incubation at 37 ◦C for 30 min  inside a sealed tube. Finally, 1 ml
of 1 g/ml Apo-B100 (A5353, Sigma, USA) in saline was added
to 1 ml  of the DiI-labeled PC-coated AuNPs and incubated for 3 h
at 37 ◦C. The TPLs were re-dispersed in saline and residual PC,
Apo, and DMSO solvent were removed by centrifuging twice at
20,000 × g for 5 min. Remaining aggregates were removed by ﬁltra-
tion using a 100 nm cutoff ﬁlter. Both their hydrodynamic diameter
and their PDI were determined by DLS measurements (Nano-ZS,
Sysmex, Netherlands). Particle number data (%) were obtained
from distribution analyses of the non-negative linear least squares
method.
2.2. In vitro experiments
Endothelial cells (ECs) (bEnd.3, ATCC, USA) from mouse brains
were cultured in cell culture medium (DMEM, Wako, Japan), sup-
plemented with 10% heat-inactivated fetal bovine serum (Bio
West, France) and 0.1% gentamycin (Sigma–Aldrich, USA). Incu-
bation was carried out at 37 ◦C in a humidiﬁed atmosphere of
5% CO2. The ECs were seeded to a density of 0.7 × 104 cells/cm2
onto glass plates (1.1 cm2) that were coated with rat-tail collagen
to a density of 5 g/cm2 inside ﬂat bottom 24-well plates (area:
1.55 × 1.55 cm2, height: 1.75 cm). ECs that grew to sub-conﬂuence,
corresponding to ﬁnal cell densities of 2.5 × 104 cells/cm2, were
treated with TPL for different incubation times (6 and 12 h). 100 l
of TPL were added to 900 l of the cell medium to achieve a
ﬁnal concentration of 2.5 g/ml. The TPL-containing cell culture
medium was replaced with non-TPL-enriched cell medium 30 min
after the end of the 12 h incubation. The ECs were then washed
twice with PBS and ﬁxed with 4% paraformaldehyde. For the
immunocytochemical analyses, ECs were blocked with 3% goat
serum for 20 min and were incubated overnight with primary anti-
bodies to clathrin HC H-300 (sc-9069, Santa Cruz Biotechnology,
USA), caveolin-1 (C-term), LRP8, and LDL receptor (C-term) (1249-
1, 3156-1, and 1956-1, Epitomics Inc., USA) at 4 ◦C. They were
subsequently incubated with secondary antibodies: Alexa Fluor®
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88 goat anti-rabbit IgG (A11034, Molecular probes, USA) and
heir nuclei were stained using H33342 (B2261, Sigma–Aldrich,
SA). Cell imaging was achieved using a confocal microscope
Leica SP-II, Leica, Germany) with a 63× oil immersion objective.
ndothelial cell vesicle with internalized TPL was  determined via
EM.
.3. In vivo experiments
100  l of 12.5 or 250 g/ml saline-diluted TPLs were tail-
ein-injected into C57BL/6J mice. After 24 h they were killed
y an intraperitoneal injection of pentobarbital diluted in saline
nd perfused via the heart with 2–5 ml  of 0.01 M PBS and 4%
araformaldehyde. The ﬂow rate was 1 ml/min. The brains were
emoved and ﬁxed with 4% paraformaldehyde in PBS for 2 days.
fter dehydration in 5% sucrose, the samples were sectioned to
 thickness of 10 m along the sagittal surfaces using a micro-
ome (LS-113, Yamato, Japan). Serial sections were cut from the
nteraural side of the mouse brain. For immunohistochemical anal-
ses of the brain, the sections were incubated overnight with
he primary rabbit polyclonal anti-Olig2 antibody (AB9610, Mil-
ipore, USA) at 4 ◦C. Subsequently, the sections were incubated
ith secondary antibodies: Alexa Fluor® 488 chicken anti-rabbitgG (A21441, Molecular probes, USA). Brain ECs were stained using
ITC-conjugated TOMATO lectin (FL-1171, Vector Laboratories,
SA). The cell nuclei were stained using H33342. The ﬂuorescent
ignals from Olig2 and TPLs in the brain sections were analyzed by
ig. 1. Preparation and characterization of tunable plasma lipoproteins. (A) The schemat
ssembly steps involved in the production process of tunable plasma lipoproteins (TPLs)
2)  labeled with the cell tracker CM-DiI for ﬂuorescent imaging. Finally, (3) apolipoprote
engths of saturated fatty acid hydrocarbon chains (6:0, 8:0, 10:0, 12:0, 14:0, 16:0, and 18
icrographs of AuNPs, PC(10:0)-coated AuNPs, and TPLs: AuNP/PC(10:0)/Apo-B100. Arrow
t  the particle surface. The PC layer thickness is 3 nm (see a magniﬁed view). (D) Hydrodyochem. Eng. Aspects 442 (2014) 157– 163 159
ﬂuorescence microscopy (BZ-9000, KEYENCE, Japan) with a Plan
Apo 20×/0.75 DIC N2 objective lens.
2.4. Statistical analysis
Statistical  signiﬁcance was  determined by Student’s t-test
(Fig. 2B andSupplementary Fig. 2B) and Tukey’s test (Fig. 3C). Dif-
ferences were considered signiﬁcant with a P value; *P < 0.005 by
Student’s t-test, * P < 0.05 by Tukey’s test.
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.
colsurfa.2013.05.053.
3.  Results and discussion
3.1.  Development of tunable plasma lipoproteins
The structure of PLs and the self-assembly processes of TPLs
are depicted in Fig. 1A. The term “tunable” is used to refer to
reﬁnement in terms of size and shape, phospholipid and protein
coating, or delivery routes. To synthesize the TPLs, AuNPs were
used to assemble the TPL cores. AuNPs have negative charges at
the hydrophobic surfaces. This AuNP behaves likes a hydropho-
bic solution, and therefore constitutes an aqueous dispersion of
insoluble solid particles [20]. AuNPs were then functionalized with
biomolecules containing PCs and Apo-B100, which are common
components of LDLs [8]. The synthesis was based on a self-assembly
ic illustration of plasma lipoproteins (PLs) and the schematic depiction of the self-
. Gold nanoparticles (AuNPs) were (1) coated with phosphatidylcholines (PCs) and
in-B100 were added. (B) Images of TPL-solutions produced by PCs with different
:0). Red color indicates that TPLs are dispersed in saline. (C) Transmission electron
s show the PCs (10:0) and Apo-B100. The coated layer is visible as a bright contrast
namic particle diameters of AuNPs in water and TPLs in saline.
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Fig. 2. Analyses of tunable plasma lipoproteins internalized into endothelial cells. (A) Confocal microscopy images of clathrin- and caveolin-coated vesicles in endothelial
cells (ECs) incubated with tunable plasma lipoproteins (TPLs) and saline (control). Green (Ex = 495 nm,  Em = 519 nm for Alexa Fluor® 488) indicates clathrin and caveolin.
Red signals (Ex = 553 nm,  Em = 570 nm for cell tracker CM-DiI) correspond to TPLs. The nuclei in the ECs are stained using H33342 (blue color: Ex = 355 nm, Em = 465 nm).
Merged color (yellow) indicates that clathrin and caveolin were colocalized with TPLs. Negative controls indicate that green and red signals are not due to background.
Transmission electron micrographs of an endothelial cell vesicle with internalized TPL. (B) TPL uptake after replacement of TPL-containing cell culture medium with non-
TPL-enriched cell medium after 12 h of incubation. Clearly visible is a decrease in the previously internalized TPL in the EC after 30 min. Estimations of the amount of TPL
uptake into ECs were performed by confocal microscopy. Each data point represents the mean ± S.E. of n = 5 images (237 m × 237 m). *P < 0.005 by Student’s t-test. (C)
Confocal microscopy images of low-density lipoprotein receptor-related protein 8 (LRP8) and low-density lipoprotein receptor (LDLR) in ECs incubated with TPLs. Green
(Ex = 495 nm,  Em = 519 nm for Alexa Fluor® 488) indicates LRP8 and LDLR. Red signals indicate TPLs. The EC nuclei were stained using H33342.
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arocess. PCs with different lengths of saturated fatty acid hydro-
arbon chains (6:0, 8:0, 10:0, 12:0, 14:0, 16:0, and 18:0) were
nvestigated. PCs (10:0 and 12:0) adsorbed solely to AuNP sur-
aces, which additionally increased their dispersion rate in saline
shown in Fig. 1B). However, PCs (6:0, 8:0, 14:0, 16:0, and 18:0)
ere insufﬁciently adsorbed at AuNP surfaces, and PC-uncoated
uNPs were aggregated in saline. This phenomenon can be under-
tood from the solubility (known as critical micelle concentration)
f PCs with different lengths of saturated fatty acid hydrocar-
on chains (6:0–18:0). By comparison, the PCs (14:0–18:0) were
ot dispersed in an aqueous solution due to their low solubility.
lternatively, PCs (6:0 and 8:0) were not adsorbed at AuNP sur-
aces due to their high solubility. This factor contributes to their
elf-assembly process. As shown in Fig. 1C, AuNPs, PC(10:0)-coated
uNPs, and TPLs: AuNP/PC(10:0)/Apo-B100 were observed by
EM. These results indicate that the AuNP surfaces are coated
y PCs (10:0) and Apo-B100. The surface coverage of Apo-B100
dsorbed to the PC(10:0)-coated AuNPs was 96 ± 3.1% (n = 63particle).  Dynamic light scattering (DLS) analyses were used to
conﬁrm hydrodynamic particle diameter of AuNPs and TPLs. The
hydrodynamic particle diameters were 19 ± 1 nm at 0.27% Poly-
dispersity index (PDI) (AuNPs in water) and 30 ± 2 nm at 0.44%
PDI (TPLs in saline), as shown in Fig. 1D. This result indicates
that TPLs are stable in saline. Additionally, phosphatidylglycerols
(PG) (10:0, 12:0, 14:0, 16:0, and 18:0), phosphatidic acids (PA)
(6:0, 8:0, 10:0, 12:0, 14:0, and 16:0), and phosphatidylserine
(PS) (8:0, 10:0, 12:0, 14:0, and 16:0) were investigated. Con-
sequently, PA(10:0)-, PS(14:0)-, and PG(16:0)-coated AuNPs are
observed (Supplementary Fig. 1A). AuNP/PC(10:0)/Apo-A1 and
AuNP/PC(10:0)/Apo-E4 were also produced and characterized
(Supplementary Fig. 1B). Thus, we developed a speciﬁc nan-
otechnique for TPL-preparation that is based on a self-assembly
process.
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.
colsurfa.2013.05.053.
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Fig. 3. Analyses of tunable plasma lipoproteins in the brain. (A) Pie graph showing the number of cells in the brain with TPL-uptake (cortex: Co, cerebellum: Ce, striatum: St,
amygdala: Am,  and hippocampus: Hi). Schematic of the mouse brain showing localized TPL; width of 360 m.  (B) Fluorescent microscopy images of TPL-uptake cells that
expressed oligodendrocyte transcription factor2 (Olig2). Green (Ex = 495 nm,  Em = 519 nm for Alexa Fluor® 488) represents Olig2. Red signals indicate TPLs labeled with
the cell tracker, CM-DiI (Ex = 553 nm,  Em = 570 nm). Arrows show the TPL-uptake Olig2+ cells. In order to analyze the ﬂuorescent signals of TPL uptake cells while reducing
intrinsic ﬂuorescent signals we  make a 10 m section. At this thickness it is usually only possible to ﬁnd one TPL uptake cell within a section. With a thicker section we  would
be  less likely to be able to detect TPLs. Thus, it is only possible to produce an image of a single cell. (C) Ratio of TPL uptake into Olig2+ cells per total Olig2+ cells in different
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ections per mouse). *P < 0.05 by Tukey’s test.
.2. Internalization of tunable plasma lipoproteins in endothelial
ells
The  transcytotic pathway of TPL: AuNP/PC(10:0)/Apo-B100 into
ndothelial cells (ECs) was elucidated in vitro with caveolin-coated
esicles (CAVs) and clathrin-coated vesicles (CLVs), which are
apable of mediating transcytosis from blood to the brain [21].
mmunocytochemical analyses (Fig. 2A) revealed the internaliza-
ion of TPLs at the incubation times of 6 h (caveolin images) and
2 h (clathrin images). Additionally, confocal microscopy images
f control (without TPLs) and negative control (without antibod-
es or without TPLs and antibodies) are shown. A TEM image of
PL-including example of intracellular vesicle was  observed. To
nalyze the uptake and efﬂux of TPLs in the ECs, total inten-
ity of the DiI-signals from TPLs that internalized into the ECs
ere quantiﬁed. ECs that grew to sub-conﬂuence were treated
ith TPLs with a ﬁnal mass concentration of 2.5 g/ml cell cul-
ure medium for 12 h. The TPL-containing cell culture medium was
eplaced with non-TPL-enriched cell medium after 12 h of incuba-
ion. As shown in Fig. 2C, we found a reduction in the quantity
f TPLs to 70% after 30 min. This result indicates that CAVs and
LVs in ECs play a role as frequent uptake and efﬂux carriers for
PLs. Low-density lipoprotein receptor-related protein 8 (LRP8)
nd low-density lipoprotein receptor (LDLR) were investigatedmpus: Hi). Asterisk indicates there were larger numbers of TPL-uptake Olig2+ cells
ampus. Each data point represents the mean ± S.D. of n = 3 mice (100 serial sagittal
to  identify a receptor that could be associated with TPLs in the
ECs. It is generally known that LRP8 and LDLR are required for
endocytosis of LDLs [22,23]. Moreover, LRP8 is localized in CAVs,
gene expression of LRP8 in mouse brain ECs is higher than LRP1,
LRP2, and LDLR, and LRP8 in mouse brain ECs is enriched in com-
parison to LRP8 in liver or lung ECs [23,24]. Consequently, we
chose the LRP8 and LDLR in established brain endothelial cell line
(bEnd.3 cells). From the observations of LRP8 and LDLR in ECs,
TPLs were recognized by LRP8 but not LDLR (Fig. 2E). Hence, TPLs
could acquire an EC recognition ability in the same way as PLs by
the tuning of PL components on the AuNP surfaces. Additionally,
AuNP/PC(10:0)/Apo-A1 and AuNP/PC(10:0)/Apo-E4 were also elu-
cidated in vitro. Consequently we  found that they internalized into
ECs via the CAVs and CLVs (Supplementary Fig. 2A). A reduced quan-
tity of AuNP/PC(10:0)/Apo-A1 to 63% and AuNP/PC(10:0)/Apo-E4 to
78% were also shown (Supplementary Fig. 2B). These results indi-
cate that both Apo-A1 and Apo-E4 have similar characteristics to
Apo-B100 for the internalization of TPLs into ECs.
3.3. The brain cell speciﬁcity of tunable plasma lipoproteinsTo conﬁrm transportation of TPL: AuNP/PC(10:0)/Apo-B100
across  the BBB, counts of cells which had successfully taken-up TPLs
(TPL-uptake cells) were obtained in serial sagittal brain sections at
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 thickness of 10 m.  Using a Plan Apo 20× objective lens, the opti-
al ﬁelds were scanned in all areas of the brain sections. The DiI
nduced ﬂuorescent signals of TPLs in the sections were compared
o saline injected sections and distinguished from the intrinsic ﬂu-
rescent signals (Supplementary Fig. 3A). As shown in Fig. 3A, we
ound TPL-uptake cells in the cortex (334 cells), the cerebellum (133
ells), striatum (75 cells), amygdala (36 cells), and hippocampus
59 cells) from the observation of whole brain sections (895 pieces)
reated with a 12.5 g TPL injection. Additionally TPL-accumulated
egions with a width of 360 m are shown. To identify the types of
eural cells, we examined the oligodendrocyte transcription fac-
or 2 (Olig2) in TPL-uptake cells using an immunohistochemical
nalysis.  Olig2, which is the basic helix-loop-helix transcription
actor, is essential for speciﬁcation and maturation of astrocytes
nd oligodendrocytes [25–27]. Olig2+ cells are deﬁned as imma-
ure oligodendrocyte precursor cells (OPCs) (also known as NG2
ells) [25–27]. From the analyses of 100 serial sagittal sections, we
ound TPL-uptake cells (102 cells), 54% of which were identiﬁed as
lig2+ cells, and 42% of which were identiﬁed as brain-ECs (Fig. 3B
nd Supplementary Fig. 3B). The brain ECs were shown using stain-
ng by FITC-conjugated TOMATO lectin (a known endothelial cell
arker). Fluorescent images of Olig2+ cells (without TPLs) in the
ortex are shown (control). Moreover, Fig. 3C shows there were
arger numbers of TPL-uptake Olig2+ cells in the cerebellum than
he amygdala and hippocampus, and in the cortex than the hip-
ocampus at the 25 g TPL injection amount (100 serial sagittal
ections per mouse, n = 3 mice). Although we found low numbers
f TPL-uptake Olig2+ cells (Fig. 3C), this ﬁnding would be explained
y the comparison of TPLs with LDLs. In fact, the TPL-injected mass
M) of 25 g was used. However, the naturally occurring LDL mass
M) was 135 g in 5 week-old mouse plasma (exact LDL mass was
dapted from [28]). Hence, total particle numbers (N) of TPLs and
DLs can be calculated as follows:
 = M
V
here  V is the volume per a TPL (particle diameter: 30 nm)
nd an LDL (particle diameter: 21–27 nm),  is the density of a
PL (19.32 g/cm3: gold) or an LDL (1.019–1.063 g/cm3). Calculated
ata show that total particle numbers of TPLs (particle number:
.2 × 1010 counts) were 200 times lower compared with those of
DLs (particle number: 1.9 × 1013 counts). Therefore, this analysis
nabled us to calculate the mean for low numbers of TPL-uptake
lig2+ cells. Therefore, our study is the ﬁrst evidence that tuning
f PCs and Apo-B100 on nanoparticle surfaces is especially helpful
or delivery route of glial cell.
Supplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/j.
olsurfa.2013.05.053.
. Conclusions
Malfunction of glial cells is a serious risk factor for NDs like
D, PD, and SCA generation and should be targeted for thera-
eutic intervention. At present, it is difﬁcult to adequately treat
hese diseases with clinical therapies and medication. Nanopar-
icles will enhance and enable novel possibilities in the research
rea of medicine. We  constructed speciﬁc TPLs and clearly demon-
trated their pathways to the brain and delivery to glia cells. Our
esults show that TPL-accumulations occur especially in AD, PD,
nd SCA generation regions in the brain. Hence, these ﬁndings offer
he potential to speciﬁcally control regions of ND generation. Fur-
hermore, glial cells, which had taken-up TPLs, may  relate to brain
elf-organizing processes (BSOPs), which are produced and pre-
erved by cerebral sustenance transportation across the BBB. TPLs
ay  help to ﬁght AD, PD, and SCA by elucidation of the link between
[ochem. Eng. Aspects 442 (2014) 157– 163
TPLs  and BSOPs, since AuNPs, which are used to assemble the TPL
cores, are attractive as a contrast agent for X-ray CT-imaging. We
expect that investigations into the adjustment or tuning of TPLs will
lead to key advances for human applications in the development of
effective ND theranostic methods, improve monitoring and anal-
ysis of glial cells, and allow access to innovative neurobiological
information.
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